MicrobiomeDX uses proprietary tools to profile microbiomes, identify host biomarkers, and develop applications to improve cancer outcomes. Through strategic collaborations, we support pre- and clinical evaluations of cancer therapies among cohorts, identify novel diagnostic and therapeutic targets, and contribute to the stratification of patients for therapy selection. The expertise of our founders in oncology, microbiome science, and bioinformatics allows us to pioneer new ways to investigate microbial targets for diagnostic and therapeutic applications.

Thinh Phan, MD
Co-founder, CEO
Dr. Phan brings 25 years of combined commercial and clinical experience to MicrobiomeDX. He founded Premier Genomics in 2013 and built the advanced genetics laboratory from the ground up. The lab focuses on clinically relevant genetics testing to drive personalized patient care specifically in the areas of Pharmacogenomics, Prenatal/carrier screening, Infectious Disease, and Hereditary Cancer. Dr. Phan is also a board-certified Radiation Oncologist, and has built several cancer treatment centers in the Houston area. He graduated with honors from the University of Pennsylvania in 2006 and obtained his medical degree from Baylor College of Medicine in 2000. He completed his residency at University of California, and fellowship at UT MD Anderson Cancer Center.

Jennifer Wargo, MD, MMSc
Clinical + Scientific Advisor
Dr. Wargo is co-founder of MicrobiomeDX team and is a recognized pioneer in the field. After completing her medical degree, she entered surgical residency training at the Massachusetts General Hospital/Harvard Medical School where she became interested in the biology and treatment of cancer. During her training, she completed two fellowships in surgical oncology with a focus on immunotherapy for cancer, training with Dr. Antoni Ribas and Dr. Steve Rosenberg. Dr. Wargo was recruited to the Division of Surgical Oncology at Massachusetts General Hospital in 2008 and had an active research laboratory focusing on the interface between oncogenic mutations and anti-tumor immunity. At Harvard/MGH, Dr. Wargo led clinical trials in targeted therapy and immuno-oncology and also established herself as leader in translational research and biomarker development. Dr. Wargo also made groundbreaking discoveries leading to therapeutic strategies to enhance responses to therapy. She began microbiome-related research in 2010 in collaboration with investigators from the Massachusetts Institute of Technology (MIT) and the Broad Institute. Dr. Wargo was recruited to UT MD Anderson Cancer Center in 2013 where she holds a title as Associate Professor of Surgery and Genomic Medicine and helps lead the Moon Shot Program for patients with cancer. Dr. Wargo has an active research laboratory and began a major effort to characterize the oral, tumor, and gut microbiome in patients with cancer in 2013. Through these studies, she and her team made novel observations regarding the potential role of the gut microbiome in modulating immune responses and treatment response in patients with cancer being treated with immunotherapy. Dr. Wargo brings clinical expertise as well, and runs several immunotherapy-related clinical trials.

Nadim Ajami, PhD
Dr. Ajami is a field-recognized scientist with 16 years of training and experience and over 100 publications in the fields of microbiome science, virology, and microbiology. Prior to joining MicrobiomeDX as Chief Science Officer, Dr. Ajami was an Assistant Professor leading bioinformatic and scientific research groups at the world-renowned Alkek Center for Metagenomics and Microbiome Research (CMMR), at Baylor College of Medicine, in Houston, Texas. For the past six years, Dr. Ajami positioned the CMMR as an international hub for the development and implementation of advanced technologies and as pioneer in the field of microbiome research and metagenomics by scaling up the academic service center and engaging in projects to further the understand of the host-microbe relationship. Dr. Ajami’s work has led to numerous funded awards and publications in top-tier journals highlighting the role of microbes and microbial communities in communicable and non-communicable diseases including gastrointestinal and respiratory infections, nutritional disorders, autism, diabetes, and cancer. Dr. Ajami directs the scientific functions of MicrobiomeDx including basic and applied research projects and the development of new technologies and products.

Katherine Burton, MBA
Ms. Burton brings 15 years of commercial health care experience to MicrobiomeDX. She serves as Executive Director of Premier Genomics, and has also held in-house and consulting roles spanning brand management, marketing, and commercialization at Bayer HealthCare, Genzyme, and Raptor Pharmaceuticals, representing product brands in the orphan drug, medical device, and nutritionals categories. She earned her BA from Boston University in 2000 and her MBA from New York University in 2007.